Skip to main content
Log in

Do small increases in serum ferritin impact prognosis in lower-risk MDS patients?

  • Letter to the Editor
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Kawabata H, Usuki K, Shindo-Ueda M, Kanda J, Tohyama K, Matsuda A, et al. Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes. Int J Hematol. 2019;110:533–42.

    Article  CAS  Google Scholar 

  2. Pileggi C, Di Sanzo H, Mascaro V, Marafioti MG, Costanzo FS, Pavia M. Role of serum ferritin level on overall survival in patients with myelodysplastic syndromes: Results of a meta-analysis of observational studies. PLoS ONE. 2017;12:e0179016.

    Article  Google Scholar 

  3. Park S, Sapena R, Kelaidi C, Vassilieff D, Bordessoule D, Stamatoullas A, et al. Ferritin level at diagnosis is not correlated with poorer survival in non-RBC transfusion dependent lower risk de novo MDS. Leuk Res. 2011;35:1530–3.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was conducted with partial support from National Council for Scientific and Technological Development (CNPq).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anacelia Gomes de Matos Mota.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mota, A.G.M., da Silva Mendonça, P., Ribeiro Junior, H.L. et al. Do small increases in serum ferritin impact prognosis in lower-risk MDS patients?. Int J Hematol 111, 742–744 (2020). https://doi.org/10.1007/s12185-020-02848-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-020-02848-3

Navigation